P. M. Sharp and B. H. Hahn, Origins of HIV and the AIDS pandemic, Cold Spring Harb Perspect Med, vol.1, 2011.

B. F. Keele, J. H. Jones, K. A. Terio, J. D. Estes, R. S. Rudicell et al., Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz, Nature, vol.460, pp.515-519, 2009.

R. S. Rudicell, H. Jones, J. Wroblewski, E. E. Learn, G. H. Li et al., Impact of simian immunodeficiency virus infection on chimpanzee population dynamics, PLoS Pathog, vol.6, p.1001116, 2010.

K. A. Terio, M. J. Kinsel, J. Raphael, T. Mlengeya, I. Lipende et al., Pathologic lesions in chimpanzees (Pan trogylodytes schweinfurthii) from Gombe National Parks, J Zoo Wildl Med, vol.42, pp.597-607, 2004.

E. Bailes, F. Gao, F. Bibollet-ruche, V. Courgnaud, M. Peeters et al., Hybrid origin of SIV in chimpanzees, Science, vol.300, p.1713, 2003.

B. F. Keele, F. Van-heuverswyn, Y. Li, E. Bailes, J. Takehisa et al., Chimpanzee reservoirs of pandemic and nonpandemic HIV-1, Science, vol.313, pp.523-526, 2006.

Y. Li, J. Ndjango, G. H. Learn, M. A. Ramirez, B. F. Keele et al., Eastern chimpanzees, but not bonobos, represent a simian immunodeficiency virus reservoir, J Virol, vol.86, pp.10776-10791, 2012.

M. L. Santiago, C. M. Rodenburg, S. Kamenya, F. Bibollet-ruche, F. Gao et al., SIVcpz in wild chimpanzees, Science, vol.295, p.465, 2002.

M. L. Santiago, M. Lukasik, S. Kamenya, Y. Li, F. Bibollet-ruche et al., Foci of endemic simian immunodeficiency virus infection in wild-living eastern chimpanzees, 2003.

, J Virol, vol.77, pp.7545-7562, 2003.

R. S. Rudicell, A. K. Piel, F. Stewart, D. L. Moore, G. H. Learn et al., High prevalence of simian immunodeficiency virus infection in a community of savanna chimpanzees, J Virol, vol.85, pp.9918-9928, 2011.

F. Van-heuverswyn, Y. Li, E. Bailes, C. Neel, B. Lafay et al., Genetic diversity and phylogeographic clustering of SIVcpzPtt in wild chimpanzees in Cameroon, Virology, vol.368, pp.155-171, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00412886

A. K. Piel, F. A. Stewart, L. Pintea, Y. Li, M. A. Ramirez et al., The Malagarasi River does not form an absolute barrier to chimpanzee movement in western Tanzania, PLoS One, vol.8, p.58965, 2013.

F. Van-heuverswyn, Y. Li, C. Neel, E. Bailes, B. F. Keele et al., Human immunodeficiency viruses: SIV infection in wild gorillas, Nature, vol.444, p.164, 2006.

L. Etienne, S. Locatelli, A. Ayouba, A. Esteban, C. Butel et al., Noninvasive follow-up of simian immunodeficiency virus infection in wildliving nonhabituated western lowland gorillas in Cameroon, J Virol, vol.86, pp.9760-9772, 2012.

J. Takehisa, M. H. Kraus, A. Ayouba, E. Bailes, F. Van-heuverswyn et al., Origin and biology of simian immunodeficiency virus in wild-living western gorillas, J Virol, vol.83, pp.1635-1648, 2009.

M. D'arc, A. Ayouba, A. Esteban, G. H. Learn, V. Boué et al., Origin of the HIV-1 group O epidemic in western lowland gorillas, Proc Natl Acad Sci, 2015.

P. D. Walsh, K. A. Abernethy, M. Bermejo, R. Beyers, D. Wachter et al., Catastrophic ape decline in western equatorial Africa, Nature, vol.422, pp.611-614, 2003.

R. A. Weiss and J. L. Heeney, Infectious diseases: an ill wind for wild chimps?, Nature, vol.460, pp.470-471, 2009.

S. J. Ryan and P. D. Walsh, Consequences of non-intervention for infectious disease in African great apes, PLoS One, vol.6, 2011.

J. L. Heeney, E. Rutjens, E. J. Verschoor, H. Niphuis, P. Ten-haaft et al., Transmission of simian immunodeficiency virus SIVcpz and the evolution of infection in the presence and absence of concurrent human immunodeficiency virus type 1 infection in chimpanzees, J Virol, vol.80, pp.7208-7218, 2006.

P. N. Fultz, H. M. Mcclure, R. B. Swenson, C. R. Mcgrath, A. Brodie et al., Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome, J Virol, vol.58, pp.116-124, 1986.

F. J. Novembre, J. De-rosayro, S. Nidtha, O. Neil, S. P. Gibson et al., Rapid CD4 ? T-cell loss induced by human immunodeficiency virus type 1(NC) in uninfected and previously infected chimpanzees, J Virol, vol.75, pp.1533-1539, 2001.

S. L. Hu, P. N. Fultz, H. M. Mcclure, J. W. Eichberg, E. K. Thomas et al.,

, Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees, Nature, vol.328, pp.721-723

B. M. Altevogt, D. E. Pankevich, M. K. Shelton-davenport, and J. P. Kahn, 2011. Chimpanzees in biomedical and behavioral research: assessing the necessity. Institute of Medicine (US) and National Research Council (US) Committee on the Use of Chimpanzees in Biomedical and Behavioral Research

K. L. Warfield, J. E. Goetzmann, J. E. Biggins, M. B. Kasda, R. C. Unfer et al., Vaccinating captive chimpanzees to save wild chimpanzees, Proc Natl Acad Sci U S A, vol.111, pp.8873-8876, 2014.

R. A. Weiss, Immunotherapy for HIV infection, N Engl J Med, vol.370, pp.379-380, 2014.

L. M. Walker, S. K. Phogat, C. Wagner, D. Phung, P. Goss et al., Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target, Science, vol.326, pp.285-289, 2009.

L. M. Walker, M. Huber, K. J. Doores, E. Falkowska, R. Pejchal et al., Broad neutralization coverage of HIV by multiple highly potent antibodies, Nature, vol.477, pp.466-470, 2011.

X. Wu, Z. Yang, Y. Li, C. Hogerkorp, W. R. Schief et al., Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1, Science, vol.329, pp.856-861, 2010.

A. B. Balazs, J. Chen, C. M. Hong, D. S. Rao, L. Yang et al., Antibody-based protection against HIV infection by vectored immunoprophylaxis, Nature, vol.481, pp.81-84, 2012.

P. R. Johnson, B. C. Schnepp, J. Zhang, M. J. Connell, S. M. Greene et al., Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys, Nat Med, vol.15, pp.901-906, 2009.

A. J. Hessell, P. Poignard, M. Hunter, L. Hangartner, D. M. Tehrani et al., Effective, lowtiter antibody protection against low-dose repeated mucosal SHIV challenge in macaques, Nat Med, vol.15, pp.951-954, 2009.

J. R. Mascola, G. Stiegler, T. C. Vancott, H. Katinger, C. B. Carpenter et al., Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies, Nat Med, vol.6, pp.207-210, 2000.

A. J. Hessell, E. G. Rakasz, P. Poignard, L. Hangartner, G. Landucci et al., Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers, PLoS Pathog, vol.5, p.1000433, 2009.

F. Klein, A. Halper-stromberg, J. A. Horwitz, H. Gruell, J. F. Scheid et al., HIV therapy by a combination of broadly neutralizing antibodies in humanized mice, Nature, vol.492, pp.118-122, 2012.

M. Shingai, Y. Nishimura, F. Klein, H. Mouquet, O. K. Donau et al., Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia, Nature, vol.503, pp.277-280, 2013.

D. H. Barouch, J. B. Whitney, B. Moldt, F. Klein, T. Y. Oliveira et al., Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIVinfected rhesus monkeys, Nature, vol.503, pp.224-228, 2013.

A. B. Balazs, Y. Ouyang, C. M. Hong, J. Chen, S. M. Nguyen et al., Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission, Nat Med, vol.20, pp.296-300, 2014.

M. G. Kaplitt, A. Feigin, C. Tang, H. L. Fitzsimons, P. Mattis et al., Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial, Lancet, vol.369, pp.60982-60991, 2007.

A. V. Cideciyan, W. W. Hauswirth, T. S. Aleman, S. Kaushal, S. B. Schwartz et al., Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year, Hum Gene Ther, vol.20, pp.999-1004, 2009.

A. C. Nathwani, E. G. Tuddenham, S. Rangarajan, C. Rosales, J. Mcintosh et al., Adenovirus-associated virus vector-mediated gene transfer in hemophilia B, N Engl J Med, vol.365, pp.2357-2365, 2011.

A. M. Maguire, F. Simonelli, E. A. Pierce, E. N. Pugh, F. Mingozzi et al., Safety and efficacy of gene transfer for Leber's congenital amaurosis, N Engl J Med, vol.358, pp.2240-2248, 2008.

A. D. Lewis, R. Chen, D. C. Montefiori, P. R. Johnson, and K. R. Clark, Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer, J Virol, vol.76, pp.8769-8775, 2002.

S. Mehandru, B. Vcelar, T. Wrin, G. Stiegler, B. Joos et al., Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection, J Virol, vol.81, pp.11016-11031, 2007.

A. Trkola, H. Kuster, P. Rusert, B. Joos, M. Fischer et al., Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies, Nat Med, vol.11, pp.615-622, 2005.

P. D. Kwong and J. R. Mascola, Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies, Immunity, vol.37, pp.412-425, 2012.

F. Klein, H. Mouquet, P. Dosenovic, J. F. Scheid, L. Scharf et al., Antibodies in HIV-1 vaccine development and therapy, Science, vol.341, pp.1199-1204, 2013.
URL : https://hal.archives-ouvertes.fr/pasteur-00861957

D. R. Burton, P. Poignard, R. L. Stanfield, and I. A. Wilson, Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses, Science, vol.337, pp.183-186, 2012.

J. Huang, G. Ofek, L. Laub, M. K. Louder, N. A. Doria-rose et al., Broad and potent neutralization of HIV-1 by a gp41-specific human antibody, Nature, vol.491, pp.406-412, 2012.

M. B. Zwick, A. F. Labrijn, M. Wang, C. Spenlehauer, E. O. Saphire et al., Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41, J Virol, vol.75, pp.10892-10905, 2001.

X. Wu, T. Zhou, J. Zhu, B. Zhang, I. Georgiev et al.,

L. , Y. Y. Yang, Z. , Y. Z. Zhang, Z. Bonsignori et al., Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing, Science, vol.333, pp.1593-1602, 2011.

H. Mouquet, L. Scharf, Z. Euler, Y. Liu, C. Eden et al., Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies, 2012.

, Proc Natl Acad Sci U S A, vol.109, pp.3268-3277

J. Huang, B. H. Kang, M. Pancera, J. H. Lee, T. Tong et al., Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface, Nature, vol.515, pp.138-142, 2014.

L. Scharf, J. F. Scheid, J. H. Lee, A. P. West, . Jr et al., Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike, Cell Rep, vol.7, pp.785-795, 2014.

C. Blattner, J. H. Lee, K. Sliepen, R. Derking, E. Falkowska et al., Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers, Immunity, vol.40, pp.669-680, 2014.

E. Falkowska, K. M. Le, A. Ramos, K. J. Doores, J. H. Lee et al., Broadly neutralizing HIV antibodies define a glycandependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers, Immunity, vol.40, pp.657-668, 2014.

A. Trkola, T. J. Ketas, K. A. Nagashima, L. Zhao, T. Cilliers et al., Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140, J Virol, vol.75, pp.579-588, 2001.

A. Dimitrov, Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection, Curr Opin Investig Drugs, vol.8, pp.653-661, 2007.

R. Song, D. A. Oren, D. Franco, M. S. Seaman, and D. D. Ho, Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity, Nat Biotechnol, vol.31, pp.1047-1052, 2013.

C. S. Pace, R. Song, C. Ochsenbauer, C. D. Andrews, D. Franco et al., Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1, Proc Natl Acad Sci U S A, vol.110, pp.13540-13545, 2013.

D. J. Capon, S. M. Chamow, J. Mordenti, S. A. Marsters, T. Gregory et al., Designing CD4 immunoadhesins for AIDS therapy, Nature, vol.337, pp.525-531, 1989.

A. P. West, . Jr, R. P. Galimidi, C. P. Foglesong, P. N. Gnanapragasam et al., Evaluation of CD4-CD4i antibody architectures yields potent, broadly cross-reactive anti-human immunodeficiency virus reagents, J Virol, vol.84, pp.261-269, 2010.

M. R. Gardner, L. M. Kattenhorn, H. R. Kondur, M. Von-schaewen, T. Dorfman et al., AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges, Nature, vol.519, pp.87-91, 2015.

M. S. Seaman, H. Janes, N. Hawkins, L. E. Grandpre, C. Devoy et al., Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies, J Virol, vol.84, pp.1439-1452, 2010.

P. Hraber, B. T. Korber, A. S. Lapedes, R. T. Bailer, M. S. Seaman et al., Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies, J Virol, vol.88, pp.12623-12643, 2014.

F. J. Novembre, M. Saucier, D. C. Anderson, S. A. Klumpp, O. Neil et al., Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1, J Virol, vol.71, pp.4086-4091, 1997.

M. Peeters, K. Fransen, E. Delaporte, M. Van-den-haesevelde, G. M. Gershy-damet et al., Isolation and characterization of a new chimpanzee lentivirus (simian immunodeficiency virus isolate cpz-ant) from a wild-captured chimpanzee, AIDS, vol.6, pp.447-451, 1992.

T. Huet, R. Cheynier, A. Meyerhans, G. Roelants, and S. Wain-hobson, Genetic organization of a chimpanzee lentivirus related to HIV-1, Nature, vol.345, pp.356-359, 1990.

F. Bibollet-ruche, F. Gao, E. Bailes, S. Saragosti, E. Delaporte et al., Complete genome analysis of one of the earliest SIVcpzPtt strains from Gabon (SIVcpzGAB2), AIDS Res Hum Retroviruses, vol.20, pp.1377-1381, 2004.

J. Takehisa, M. H. Kraus, J. M. Decker, Y. Li, B. F. Keele et al., Generation of infectious molecular clones of simian immunodeficiency virus from fecal consensus sequences of wild chimpanzees, J Virol, vol.81, pp.7463-7475, 2007.

F. Bibollet-ruche, A. Heigele, B. F. Keele, J. L. Easlick, J. M. Decker et al., Efficient SIVcpz replication in human lymphoid tissue requires viral matrix protein adaptation, J Clin Invest, vol.122, pp.1644-1652, 2012.

C. Hvilsom, F. Carlsen, H. R. Siegismund, S. Corbet, E. Nerrienet et al., Genetic subspecies diversity of the chimpanzee CD4 virus-receptor gene, Genomics, vol.92, pp.322-328, 2008.

M. R. Posner, T. Hideshima, T. Cannon, M. Mukherjee, K. H. Mayer et al., An IgG human monoclonal antibody that reacts with HIV-1/ GP120, inhibits virus binding to cells, and neutralizes infection, J Immunol, vol.146, pp.4325-4332, 1991.

C. F. Barbas, . Iii, T. A. Collet, W. Amberg, P. Roben et al., Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries, J Mol Biol, vol.230, pp.812-823, 1993.

R. Diskin, J. F. Scheid, P. M. Marcovecchio, A. P. West, . Jr et al., Increasing the potency and breadth of an HIV antibody by using structure-based rational design, Science, vol.334, pp.1289-1293, 2011.

L. E. Mccoy, A. F. Quigley, N. M. Strokappe, B. Bulmer-thomas, M. S. Seaman et al., Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization, J Exp Med, vol.209, pp.1091-1103, 2012.

L. Chen, Y. D. Kwon, T. Zhou, X. Wu, O. Dell et al., Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120, Science, vol.326, pp.1123-1127, 2009.

T. Zhou, I. Georgiev, X. Wu, Z. Yang, K. Dai et al.,

L. Shapiro, G. J. Nabel, J. R. Mascola, and P. D. Kwong, Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01, Science, vol.329, pp.811-817, 2010.

Y. Li, S. O'dell, L. M. Walker, X. Wu, J. Guenaga et al., Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01, J Virol, vol.85, pp.8954-8967, 2011.

A. Trkola, A. B. Pomales, H. Yuan, B. Korber, P. J. Maddon et al., Crossclade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG, J Virol, vol.69, pp.6609-6617, 1995.

C. N. Scanlan, R. Pantophlet, M. R. Wormald, O. Saphire, E. Stanfield et al., The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1¡2 mannose residues on the outer face of gp120, J Virol, vol.76, pp.7306-7321, 2002.

D. Sok, K. J. Doores, B. Briney, K. M. Le, K. L. Saye-francisco et al., Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV, Sci Transl Med, vol.6, pp.236-63, 2014.

J. S. Mclellan, M. Pancera, C. Carrico, J. Gorman, J. Julien et al., Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9, vol.480, pp.336-343, 2011.

N. A. Doria-rose, I. Georgiev, O. Dell, S. Chuang, G. Staupe et al., A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies, J Virol, vol.86, pp.696-708, 2012.

M. Sagar, X. Wu, S. Lee, and J. Overbaugh, Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity, J Virol, vol.80, pp.9586-9598, 2006.

M. J. Van-gils, E. M. Bunnik, B. D. Boeser-nunnink, J. A. Burger, M. Terlouw-klein et al., Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies, J Virol, vol.85, pp.6986-6995, 2011.

A. Forsman, E. Beirnaert, M. M. Aasa-chapman, B. Hoorelbeke, K. Hijazi et al., Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120, J Virol, vol.82, pp.12069-12081, 2008.

N. Strokappe, A. Szynol, M. Aasa-chapman, A. Gorlani, F. Quigley et al., Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C, PLoS One, vol.7, 2012.

P. Acharya, T. S. Luongo, I. S. Georgiev, J. Matz, S. D. Schmidt et al., Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor-and CD4-binding sites, J Virol, vol.87, pp.10173-10181, 2013.
URL : https://hal.archives-ouvertes.fr/hal-02530765

J. Matz, P. Kessler, J. Bouchet, O. Combes, O. H. Ramos et al., Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120, J Virol, vol.87, pp.1137-1149, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00731772

L. E. Mccoy, L. Rutten, D. Frampton, A. I. Granger, L. Bashford-rogers et al., Molecular evolution of broadly neutralizing llama antibodies to the CD4-binding site of HIV-1, PLoS Pathog, vol.10, p.1004552, 2014.

N. M. Strokappe, HIV-1, how llamas help us fight the AIDS pandemic, 2013.

L. Hulsik, D. Liu, Y. Strokappe, N. M. Battella, S. El-khattabi et al., A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition, PLoS Pathog, vol.9, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01241201

V. Zacharova, V. Zachar, and A. S. Goustin, Sequence of chemokine receptor gene CCR5 in chimpanzees, a natural HIV type 1 host, AIDS Res Hum Retroviruses, vol.13, pp.1159-1161, 1997.

J. M. Jacobson, M. S. Saag, M. A. Thompson, M. A. Fischl, R. Liporace et al., Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults, J Infect Dis, vol.198, pp.1345-1352, 2008.

J. M. Jacobson, D. R. Kuritzkes, E. Godofsky, E. Dejesus, J. A. Larson et al., Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults, Antimicrob Agents Chemother, vol.53, pp.450-457, 2009.

D. R. Kuritzkes, J. Jacobson, W. G. Powderly, E. Godofsky, E. Dejesus et al.,

, Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1, J Infect Dis, vol.189, pp.286-291

C. J. Bruno and J. M. Jacobson, Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection, J Antimicrob Chemother, vol.65, pp.1839-1841, 2010.

R. Song, D. Franco, C. Kao, F. Yu, Y. Huang et al., Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients, J Virol, vol.84, pp.6935-6942, 2010.

G. P. Allaway, K. L. Davis-bruno, G. A. Beaudry, E. B. Garcia, E. L. Wong et al., Maddon PJ. 1995. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates, AIDS Res Hum Retroviruses, vol.11, pp.533-539

D. H. Smith, R. A. Byrn, S. A. Marsters, T. Gregory, J. E. Groopman et al., Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen, Science, vol.238, pp.1704-1707, 1987.

R. A. Byrn, J. Mordenti, C. Lucas, D. Smith, S. A. Marsters et al., Biological properties of a CD4 immunoadhesin, Nature, vol.344, pp.667-670, 1990.

H. Choe, W. Li, P. L. Wright, N. Vasilieva, M. Venturi et al., Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120, Cell, vol.114, pp.508-515, 2003.

T. Dorfman, M. J. Moore, A. C. Guth, H. Choe, and M. Farzan, A tyrosinesulfated peptide derived from the heavy-chain CDR3 region of an HIV-1-neutralizing antibody binds gp120 and inhibits HIV-1 infection, J Biol Chem, vol.281, pp.28529-28535, 2006.

J. A. Kwong, T. Dorfman, B. D. Quinlan, J. J. Chiang, A. A. Ahmed et al., A tyrosine-sulfated CCR5-mimetic peptide promotes conformational transitions in the HIV-1 envelope glycoprotein, J Virol, vol.85, pp.7563-7571, 2011.

J. M. Kilby, S. Hopkins, T. M. Venetta, B. Dimassimo, G. A. Cloud et al., Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry, Nat Med, vol.4, pp.1302-1307, 1998.

H. Liao, R. Lynch, T. Zhou, F. Gao, S. M. Muniralam et al., Coevolution of a broadly neutralizing HIV-1 antibody and founder virus, Nature, vol.496, pp.469-476, 2013.

H. Mouquet and M. C. Nussenzweig, HIV: roadmaps to a vaccine, Nature, vol.496, pp.441-442, 2013.

F. Gao, M. Bonsignori, H. Liao, A. Kumar, S. Xia et al., Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies, Cell, vol.158, pp.481-491, 2014.

P. D. Kwong, R. Wyatt, J. Robinson, R. W. Sweet, J. Sodroski et al., Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody, Nature, vol.393, pp.648-659, 1998.

I. S. Georgiev, N. A. Doria-rose, T. Zhou, Y. D. Do-kwon, R. P. Staupe et al., Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization, Science, vol.340, pp.751-756, 2013.

C. S. Pace, M. W. Fordyce, D. Franco, C. Kao, M. S. Seaman et al., Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope, J Acquir Immune Defic Syndr, vol.62, pp.1-9, 2013.

L. C. Burkly, D. Olson, R. Shapiro, G. Winkler, J. J. Rosa et al., Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion, J Immunol, vol.149, pp.1779-1787, 1992.

W. C. Olson, G. E. Rabut, K. A. Nagashima, D. N. Tran, D. J. Anselma et al., Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5, J Virol, vol.73, pp.4145-4155, 1999.

A. Pegu, Z. Yang, J. C. Boyington, L. Wu, S. Ko et al., Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor, Sci Transl Med, vol.6, pp.243-88, 2014.

P. Poignard, B. Moldt, K. Maloveste, N. Campos, W. C. Olson et al., Protection against high-dose highly pathogenic mucosal SIV challenge at very low serum neutralizing titers of the antibody-like molecule CD4-IgG2, PLoS One, vol.7, 2012.

R. P. Galimidi, J. S. Klein, M. S. Politzer, S. Bai, M. S. Seaman et al., Intra-spike crosslinking overcomes antibody evasion by HIV-1, Cell, vol.160, pp.433-446, 2015.

C. D. Andrews, W. R. Spreen, H. Mohri, L. Moss, S. Ford et al., Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus, Science, vol.343, pp.1151-1154, 2014.

C. D. Andrews, Y. L. Yueh, W. R. Spreen, S. Bernard, L. Boente-carrera et al., A longacting integrase inhibitor protects female macaques from repeated highdose intravaginal SHIV challenge, Sci Transl Med, vol.7, 2015.

L. Etienne, E. Nerrienet, M. Lebreton, G. T. Bibila, Y. Foupouapouognigni et al., Characterization of a new simian immunodeficiency virus strain in a naturally infected Pan troglodytes troglodytes chimpanzee with AIDS related symptoms, Retrovirology, vol.8, 2011.
URL : https://hal.archives-ouvertes.fr/pasteur-00599302

T. Humle, C. Colin, M. Laurans, and E. Raballand, Group release of sanctuary chimpanzees (Pan troglodytes) in the Haut Niger National Park, Guinea, west Africa: ranging patterns and lessons so far, Int J Primatol, vol.32, pp.456-473, 2011.

T. Migone, G. M. Subramanian, J. Zhong, L. M. Healey, A. Corey et al., Raxibacumab for the treatment of inhalational anthrax, N Engl J Med, vol.361, pp.135-144, 2009.

J. Pettitt, L. Zeitlin, H. Kim, C. Working, J. C. Johnson et al., Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail, Sci Transl Med, vol.5, 2013.

S. K. Ghosh, P. N. Fultz, E. Keddie, M. S. Saag, P. M. Sharp et al., A molecular clone of HIV-1 tropic and cytopathic for human and chimpanzee lymphocytes, Virology, vol.194, pp.858-864, 1993.

Y. Li, J. C. Kappes, J. A. Conway, R. W. Price, G. M. Shaw et al., Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes, J Virol, vol.65, pp.3973-3985, 1991.

Y. Koyanagi, S. Miles, R. T. Mitsuyasu, J. E. Merrill, H. V. Vinters et al., Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms, Science, vol.236, pp.819-822, 1987.

M. A. Larkin, G. Blackshields, N. P. Brown, R. Chenna, P. A. Mcgettigan et al., Clustal W and Clustal X version 2.0, Bioinformatics, vol.23, pp.2947-2948, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00206210

S. Guindon, J. Dufayard, V. Lefort, M. Anisimova, W. Hordijk et al., New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0, Syst Biol, vol.59, pp.307-321, 2010.
URL : https://hal.archives-ouvertes.fr/lirmm-00511784

D. T. Jones, W. R. Taylor, and J. M. Thornton, A new approach to protein fold recognition, Nature, vol.358, pp.86-89, 1992.

F. Abascal, R. Zardoya, and D. Posada, ProtTest: selection of best-fit models of protein evolution, Bioinformatics, vol.21, pp.2104-2105, 2005.

F. Ronquist and J. P. Huelsenbeck, MrBayes 3: Bayesian phylogenetic inference under mixed models, Bioinformatics, vol.19, pp.1572-1574, 2003.

L. Etienne, S. Eymard-duvernay, A. Aghokeng, C. Butel, M. Monleau et al., Single real-time reverse transcription-PCR assay for detection and quantification of genetically diverse HIV-1, SIVcpz, and SIVgor strains, J Clin Microbiol, vol.51, pp.2792-2804, 2013.

X. Wei, J. M. Decker, H. Liu, Z. Zhang, R. B. Arani et al., Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy, Antimicrob Agents Chemother, vol.46, pp.1896-1905, 2002.

M. Lopker, J. Easlick, S. Sterrett, J. M. Decker, H. Barbian et al., Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock, J Virol, vol.87, pp.5477-5492, 2013.

D. C. Montefiori, J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach et al., Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays, Current protocols in immunology, 2005.

B. Etemad-moghadam, Y. Sun, E. K. Nicholson, M. Fernandes, K. Liou et al., Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo, J Virol, vol.74, pp.4433-4440, 2000.

J. M. Decker, K. P. Zammit, J. L. Easlick, M. L. Santiago, D. Bonenberger et al., Effective activation alleviates the replication block of CCR5-tropic HIV-1 in chimpanzee CD4? lymphocytes, Virology, vol.394, pp.109-118, 2009.